Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Capricor Therapeutics (CAPR) over the last 16 years, with Dec 2024 value amounting to $9.8 million.

  • Capricor Therapeutics' Share-based Compensation rose 94.87% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 65.27%. This contributed to the annual value of $9.8 million for FY2024, which is 32.10% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Share-based Compensation of $9.8 million as of FY2024, which was up 32.10% from $7.4 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Share-based Compensation ranged from a high of $9.8 million in FY2024 and a low of $2.0 million during FY2020.
  • In the last 3 years, Capricor Therapeutics' Share-based Compensation had a median value of $7.4 million in 2023 and averaged $7.2 million.
  • Data for Capricor Therapeutics' Share-based Compensation shows a peak YoY soared of 178.56% (in 2020) over the last 5 years.
  • Capricor Therapeutics' Share-based Compensation (Yearly) stood at $2.0 million in 2020, then skyrocketed by 51.88% to $3.0 million in 2021, then spiked by 50.34% to $4.5 million in 2022, then soared by 65.80% to $7.4 million in 2023, then spiked by 32.10% to $9.8 million in 2024.